Yüklüyor......
PTEN loss is associated with worse outcome in HER2-amplified breast cancer patients but is not associated with trastuzumab resistance
PURPOSE: To investigate the clinical relevance of PTEN in HER2-amplified and HER2-non-amplified disease. EXPERIMENTAL DESIGN: We assessed PTEN status in two large adjuvant breast cancer trials (BCIRG-006 and BCIRG-005) using a PTEN IHC assay that was previously validated in a panel of 33 breast canc...
Kaydedildi:
| Yayımlandı: | Clin Cancer Res |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4417419/ https://ncbi.nlm.nih.gov/pubmed/25649019 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2993 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|